← Back to Search

Anti-tumor antibody

Carboplatin + Avastin for Breast Cancer

Phase 2
Waitlist Available
Led By Rita Nanda, MD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival
Secondary outcome measures
BRCA1 gene
Duration of Response
Response Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Carboplatin + AvastinExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
FDA approved
Bevacizumab
FDA approved

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,018 Previous Clinical Trials
734,604 Total Patients Enrolled
26 Trials studying Breast Cancer
4,759 Patients Enrolled for Breast Cancer
Genentech, Inc.Industry Sponsor
1,542 Previous Clinical Trials
568,066 Total Patients Enrolled
97 Trials studying Breast Cancer
23,218 Patients Enrolled for Breast Cancer
Rita Nanda, MDPrincipal InvestigatorUniversity of Chicago
3 Previous Clinical Trials
111 Total Patients Enrolled
3 Trials studying Breast Cancer
111 Patients Enrolled for Breast Cancer
~1 spots leftby Jul 2025